Anapole Technologies

Anapole Technologies is a private, pre-revenue medical device and drug delivery company commercializing a novel, non-invasive therapeutic platform based on Resonance Generating Fields (RGFields). The technology has shown clinical effectiveness against HIV and pre-clinical success in tuberculosis and certain cancers, positioning it as a potential paradigm shift in treatment modalities. Led by an experienced team with strong financial and military backgrounds, the company is seeking strategic partners to bring its cost-effective, scalable system to market. Its value proposition centers on high ROI for providers and broader patient access due to lower treatment costs and backward-compatible hardware upgrades.

Resonance Generating Fields (RGFields) - a patented, non-invasive therapeutic and diagnostic platform utilizing physical fields for treatment. It integrates hardware (medical equipment), software applications, and a data platform for rapid development of new diagnostics and therapies.

Anapole operates in a highly competitive space, facing entrenched pharmaceutical companies with advanced drug pipelines for oncology and HIV, as well as other medical device firms developing non-invasive therapies (e.g., focused ultrasound, radiofrequency ablation). Its success depends on demonstrating superior efficacy, safety, or cost-effectiveness compared to these established and emerging modalities.